28521254|t|CS - PEG decorated PLGA nano-prototype for delivery of bioactive compounds: A novel approach for induction of apoptosis in HepG2 cell line
28521254|a|Polymer - based nanoparticles are used as vectors for cancer drug delivery. The bioactive compounds (quercetin, ellagic acid and gallic acid) are well known to be not only antioxidants but also chemopreventive candidates against various types of cancers. To circumvent the low bioavailability and the short half-life time obstacles, we hypothesized a novel PLGA nano-platform functionalized with CS and PEG to encapsulate these phytochemicals. This encapsulation will protect the compounds from the phagocytic uptake and deliver PLGA-CS-PEG nano-prototype with high biodegradability and biosafety. Three consequent types of PLGA-based nanocomposites were prepared and characterized. Furthermore, we investigated the newly synthesized nano-formulations against human hepatocellular carcinoma (HepG2) and colorectal cancer (HCT 116) cell lines using cell growth inhibition assays, followed by apoptosis and necrosis assays using flow cytometry to detect the underlying mechanism of HepG2 cell death. Through Malvern Zeta Sizer, we recorded that the average diameters of the nano-prototypes ranged from 150 to 300nm. The cytotoxic activity of quercetin, ellagic acid, and gallic acid - encapsulated PLGA, PLGA-CS, and PLGA-CS-PEG nano-prototypes it has been found that they reduce the IC50s of the HepG2 cells values by 2.2, 2.9, 2.8- folds, 1, 1.5, 2.7- folds, and 0.9, 0.7, 1.5- folds, respectively. Mechanistically, the nano-platforms of quercetin seem to be dependent on both apoptosis and necrosis, while those of ellagic acid and gallic acid are mainly dependent on apoptosis. CS - PEG -blended PLGA nano-delivery system of quercetin, ellagic acid and gallic acid can potentiate apoptosis-mediated cell death in HepG2 cell line.
28521254	0	2	CS	T103	UMLS:C0162969
28521254	5	8	PEG	T103	UMLS:C0032483
28521254	19	38	PLGA nano-prototype	T103	UMLS:C0071599
28521254	55	74	bioactive compounds	T103	UMLS:C0574031
28521254	84	92	approach	T082	UMLS:C0449445
28521254	110	119	apoptosis	T038	UMLS:C0162638
28521254	123	138	HepG2 cell line	T017	UMLS:C2717940
28521254	139	146	Polymer	T103	UMLS:C0032521
28521254	181	188	vectors	T082	UMLS:C0442335
28521254	193	199	cancer	T038	UMLS:C0007097
28521254	219	238	bioactive compounds	T103	UMLS:C0574031
28521254	240	249	quercetin	T103	UMLS:C0034392
28521254	251	263	ellagic acid	T103	UMLS:C0013900
28521254	268	279	gallic acid	T103	UMLS:C0016979
28521254	311	323	antioxidants	T103	UMLS:C0003402
28521254	333	359	chemopreventive candidates	T103	UMLS:C1516463
28521254	385	392	cancers	T038	UMLS:C0007097
28521254	496	514	PLGA nano-platform	T103	UMLS:C0071599
28521254	535	537	CS	T103	UMLS:C0162969
28521254	542	545	PEG	T103	UMLS:C0032483
28521254	567	581	phytochemicals	T103	UMLS:C0577749
28521254	619	628	compounds	T103	UMLS:C1254351
28521254	638	655	phagocytic uptake	T038	UMLS:C3888108
28521254	668	694	PLGA-CS-PEG nano-prototype	T103	UMLS:C1254351
28521254	763	788	PLGA-based nanocomposites	T103	UMLS:C1254351
28521254	899	904	human	T204	UMLS:C0086418
28521254	905	929	hepatocellular carcinoma	T038	UMLS:C2239176
28521254	931	936	HepG2	T017	UMLS:C2717940
28521254	942	959	colorectal cancer	T038	UMLS:C1527249
28521254	961	968	HCT 116	T017	UMLS:C1258005
28521254	970	980	cell lines	T017	UMLS:C0682523
28521254	987	1009	cell growth inhibition	T038	UMLS:C1512773
28521254	1010	1016	assays	T058	UMLS:C1510438
28521254	1030	1039	apoptosis	T038	UMLS:C0162638
28521254	1044	1052	necrosis	T038	UMLS:C0027540
28521254	1053	1059	assays	T058	UMLS:C1510438
28521254	1066	1080	flow cytometry	T058	UMLS:C0016263
28521254	1084	1090	detect	T058	UMLS:C0022885
28521254	1119	1124	HepG2	T017	UMLS:C2717940
28521254	1125	1135	cell death	T038	UMLS:C0007587
28521254	1257	1275	cytotoxic activity	T058	UMLS:C1551412
28521254	1279	1288	quercetin	T103	UMLS:C0034392
28521254	1290	1302	ellagic acid	T103	UMLS:C0013900
28521254	1308	1319	gallic acid	T103	UMLS:C0016979
28521254	1335	1339	PLGA	T103	UMLS:C0071599
28521254	1341	1348	PLGA-CS	T103	UMLS:C1254351
28521254	1354	1381	PLGA-CS-PEG nano-prototypes	T103	UMLS:C1254351
28521254	1394	1399	found	T033	UMLS:C0150312
28521254	1434	1445	HepG2 cells	T017	UMLS:C2717940
28521254	1577	1586	quercetin	T103	UMLS:C0034392
28521254	1616	1625	apoptosis	T038	UMLS:C0162638
28521254	1630	1638	necrosis	T038	UMLS:C0027540
28521254	1655	1667	ellagic acid	T103	UMLS:C0013900
28521254	1672	1683	gallic acid	T103	UMLS:C0016979
28521254	1708	1717	apoptosis	T038	UMLS:C0162638
28521254	1719	1721	CS	T103	UMLS:C0162969
28521254	1724	1727	PEG	T103	UMLS:C0032483
28521254	1737	1741	PLGA	T103	UMLS:C0071599
28521254	1766	1775	quercetin	T103	UMLS:C0034392
28521254	1777	1789	ellagic acid	T103	UMLS:C0013900
28521254	1794	1805	gallic acid	T103	UMLS:C0016979
28521254	1821	1839	apoptosis-mediated	T038	UMLS:C0162638
28521254	1840	1850	cell death	T038	UMLS:C0007587
28521254	1854	1869	HepG2 cell line	T017	UMLS:C2717940